Orgenesis Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ORGS Over the counter 2836 orgenesis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Orgenesis Inc.

Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies - Mar 6th, 2025 1:05 pm
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings - Jan 28th, 2025 6:00 am
Orgenesis Provides Third Quarter 2024 Business Update - Nov 13th, 2024 6:00 am
Orgenesis Commences Trading on OTCQX® Best Market - Oct 21st, 2024 6:00 am
Orgenesis Announces Reverse Stock Split - Sep 23rd, 2024 5:00 am
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia - Aug 29th, 2024 6:30 am
Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally - Aug 14th, 2024 6:30 am
Orgenesis Provides Second Quarter 2024 Business Update - Aug 8th, 2024 2:05 pm